FDA Releases Final Guidance for Prescription Drug-Related Mobile Apps

The U.S. Food and Drug Administration has issued final guidance for drug companies on developing, distributing, and labeling mobile applications used with prescription medicines. This framework clarifies when app content requires FDA submission and how apps should be referenced on drug labels. The guidance addresses previous uncertainties in the digital health sector, providing a clearer regulatory path for these integrated health technologies.